# Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

> **NCT00004935** · PHASE3 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 175 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Herceptin™ (Her)
- **DRUG:** Herceptin™ (Her) + chemo

## Key facts

- **NCT ID:** NCT00004935
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-08-30
- **Primary completion:** 2014-11-06
- **Final completion:** 2022-03-31
- **Target enrollment:** 175 (ACTUAL)
- **Why stopped:** Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely.
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004935, "Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*